JPMorgan Adds Syndax Pharmaceuticals (SNDX) to Analyst Focus List

May 21, 2024 6:34 AM EDT Send to a Friend
JPMorgan analyst Anupam Rama reiterated an Overweight rating and $34.00 price target on Syndax Pharmaceuticals (NASDAQ: SNDX).The analyst comments "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login